Trial Profile
Comparative study of various DOACs for atrial fibrillation after cardiac surgery(prospective observation research)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis
- Focus Adverse reactions
- 06 Feb 2021 Status changed from active, no longer recruiting to completed.
- 09 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2018 New trial record